drugset / Trial / NCT06521567
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
Timeline
- Start
- 2025-03-06
- Primary completion
- 2026-10-13
- Completion
- 2026-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobolimab | Monoclonal antibody | — | — |
| Subject | Dostarlimab | Monoclonal antibody | — | — |